zantac news - Search News

The New York Times · 2d

Zantac’s Developer Settles Lawsuits Claiming Cancer Link

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

Reuters on MSN · 2d

GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement

Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

2don MSN

GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

2d

FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...

2don MSN

UK borrowing costs hit three-month high amid ‘buyers’ strike’ fears; GSK’s shares surge after $2.2bn Zantac settlement – business live

Yield on 10-year UK government debt hits highest since early July, while inflation has eased in the US. 15:39 ...

2d

GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results